Harmony Biosciences Holdings, Inc.
BP1.15205
orexin-2 receptor agonist
Resolved
7days ago
Phase 1 readout · Jun 30, 2026
What's at stake
Phase 1 trial results for BP1.15205 in orexin-2 receptor agonist are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Anticipates clinical PK data in mid-2026”